Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 5:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 367 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chimeric Antigen Receptor T-cell Clear all
Withdrawn Phase 1 Interventional

3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA

NCT02439788
View directory record Official record
Conditions
Neuroblastoma
Interventions
cyclophosphamide, Fludarabine, GINAKIT Cells
Drug · Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 30, 2026, 5:11 AM EDT
Completed Phase 1 Interventional

BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma

NCT03070327
View directory record Official record
Conditions
Multiple Myeloma
Interventions
EGFRt/BCMA-41BBz CAR T cell, Cyclophosphamide, Lenalidomide.
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 30, 2026, 5:11 AM EDT
Active, not recruiting Phase 1 Interventional

T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors

NCT02442297
View directory record Official record
Conditions
Brain Tumor, Recurrent, Brain Tumor, Refractory
Interventions
HER2-specific T cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2037
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 30, 2026, 5:11 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma

NCT03548207
View directory record Official record
Conditions
Multiple Myeloma
Interventions
JNJ-68284528
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
17
States / cities
Phoenix, Arizona • Duarte, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 30, 2026, 5:11 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma

NCT03430011
View directory record Official record
Conditions
Multiple Myeloma
Interventions
JCARH125, JCARH125 + anakinra
Biological
Lead sponsor
Juno Therapeutics, a Subsidiary of Celgene
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
20
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 30, 2026, 5:11 AM EDT
Completed Phase 1Phase 2 Interventional

'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL

NCT04601831
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
Focal radiation therapy (RT)
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 30, 2026, 5:11 AM EDT
Active, not recruiting Phase 1 Interventional

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors

NCT05103631
View directory record Official record
Conditions
Liver Cell Carcinoma, Solid Tumor, Wilms Tumor, Malignant Rhabdoid Tumor, Yolk Sac Tumor, Rhabdomyosarcoma, Liposarcoma, Embryonal Sarcoma of the Liver
Interventions
CATCH T cells
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2040
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 30, 2026, 5:11 AM EDT
Withdrawn Phase 1 Interventional

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

NCT06094842
View directory record Official record
Conditions
Prostate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions
Bendamustine, Biopsy, Biospecimen Collection, Bone Scan, Bridge Therapy, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Leukapheresis, Multigated Acquisition Scan, T-cell Receptor-engineered T-cells, X-Ray Imaging
Drug · Procedure · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 30, 2026, 5:11 AM EDT
Completed Phase 1 Interventional

CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies

NCT02529813
View directory record Official record
Conditions
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD19 Positive, Minimal Residual Disease, Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
Interventions
Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Tisagenlecleucel
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 30, 2026, 5:11 AM EDT
Enrolling by invitation No phase listed Observational

Prevalence and Clinical Manifestations of Cannabis Withdrawal in Hospitalized Patients With Hematological Malignancies Undergoing Bone Marrow Transplant (BMT) or Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

NCT07594496
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 30, 2026, 5:11 AM EDT
Recruiting Phase 1 Interventional

Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer

NCT05225363
View directory record Official record
Conditions
Platinum-Resistant Ovarian Carcinoma
Interventions
Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 30, 2026, 5:11 AM EDT
Recruiting Phase 1 Interventional

CD4CAR for CD4+ Leukemia and Lymphoma

NCT03829540
View directory record Official record
Conditions
T-cell Lymphoma, T-cell Leukemia
Interventions
CD4CAR
Biological
Lead sponsor
Huda Salman
Other
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2042
U.S. locations
6
States / cities
Miami, Florida • Indianapolis, Indiana • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 30, 2026, 5:11 AM EDT
Terminated Phase 1 Interventional

Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma

NCT03448978
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Descartes-08, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Cartesian Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Bethesda, Maryland • Oklahoma City, Oklahoma • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 30, 2026, 5:11 AM EDT
Completed Phase 1 Interventional Results available

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

NCT03448393
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, B Cell, B-Cell Lymphoma, B-Cell Leukemia, Acute Lymphoid Leukemia, B-Non Hodgkin Lymphoma, B-NHL, B-All, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia
Interventions
CD19/CD22 CAR T-Cells, Fludarabine, Cyclophosphamide, Apheresis, Anti-emetic, Diphenhydramine, Acetaminophen, ECG, ECHO, MRI Brain, Bone marrow biopsy, Cardiac MRI
Biological · Drug · Procedure + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 39 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 30, 2026, 5:11 AM EDT
Recruiting Phase 1 Interventional

Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)

NCT07200089
View directory record Official record
Conditions
Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Interventions
NT-I7, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 30, 2026, 5:11 AM EDT
Withdrawn Phase 1 Interventional

Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)

NCT01316146
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
Interventions
CAR.CD30 T cells
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 30, 2026, 5:11 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas

NCT02650999
View directory record Official record
Conditions
CD19+ Diffuse Large B-cell Lymphomas, Follicular Lymphomas, Mantle Cell Lymphomas
Interventions
Pembrolizumab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 30, 2026, 5:11 AM EDT
Active, not recruiting Phase 1 Interventional

Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies

NCT05797233
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell
Interventions
Anti-CD19 and anti-CD20 bicistronic CAR T- cells, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 5:11 AM EDT
Recruiting Phase 1 Interventional

Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis

NCT06298019
View directory record Official record
Conditions
Dermatomyositis
Interventions
KYV-101
Biological
Lead sponsor
Stanford University
Other
Eligibility
25 Years to 72 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2039
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 30, 2026, 5:11 AM EDT
Completed Phase 1 Interventional

A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors

NCT02107963
View directory record Official record
Conditions
Sarcoma, Osteosarcoma, Neuroblastoma, Melanoma
Interventions
Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 35 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 30, 2026, 5:11 AM EDT
Terminated No phase listed Observational

Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product

NCT03436771
View directory record Official record
Conditions
Non Hodgkin Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Interventions
JCAR017, JCARH125
Genetic
Lead sponsor
Juno Therapeutics, a Subsidiary of Celgene
Industry
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Duarte, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Oct 30, 2026, 5:11 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells

NCT07071909
View directory record Official record
Conditions
Malignancy, Cancer, Hematological Malignancies, Lymphoma, Leukemia, Multiple Myeloma, Solid Tumor
Interventions
Commercial CAR-T, Investigational CAR-T
Biological
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 30, 2026, 5:11 AM EDT
Terminated Early Phase 1 Interventional

Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)

NCT02640209
View directory record Official record
Conditions
LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Interventions
CART 19
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 30, 2026, 5:11 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

NCT02663297
View directory record Official record
Conditions
Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type
Interventions
ATLCAR.CD30 cells
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
3 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2037
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 30, 2026, 5:11 AM EDT